The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colon cancer: A network meta-analysis.
 
Paola Di Nardo
Travel, Accommodations, Expenses - ESMO
 
Fabiola Giudici
No Relationships to Disclose
 
Debora Basile
No Relationships to Disclose
 
Marco de Scordilli
No Relationships to Disclose
 
Sara Torresan
No Relationships to Disclose
 
Martina Bortolot
No Relationships to Disclose
 
Simone Rota
No Relationships to Disclose
 
Luisa Foltran
No Relationships to Disclose
 
Michela Guardascione
No Relationships to Disclose
 
Arianna Fumagalli
Travel, Accommodations, Expenses - Partecipation, travel and accomodation to Esmo Rare Cancers 2023 by Pharmamar
 
Claudia Noto
No Relationships to Disclose
 
Alessandra Guglielmi
No Relationships to Disclose
 
Elena Ongaro
No Relationships to Disclose
 
Fabio Puglisi
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Eisai (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Roche; Seagen